According to the study, CBLC depletion increased the sensitivity of EGFR-mutant lung cancer cells to tyrosine kinase inhibitors (TKIs), which could suggest an alternative strategy to enhance the efficacy of therapeutics in lung cancer patients by the use of combinatory treatments with TKIs and CBLC targeting molecules. This evidence concerns the gene EGFR and lung carcinoma.